ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Dizal Pharmaceuticals and Sino Biopharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Dizal PharmaceuticalsSino Biopharmaceutical
studies on the registry41471
open to participants now16163
phase 3 studies under way546
reach primary completion within a year757
programswith a study of their own in two years697+19 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDizal PharmaceuticalsSino Biopharmaceutical
Phase 100%

Sino Biopharmaceutical: 37 of its 97 programs at phase 1

  1. TQF3250phase 1
  2. TQB2101phase 1
  3. 1200mg of tqb2928 injectionphase 1
  4. Anecatibin Fumarate Capsulesphase 1
  5. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1

and 32 more — sign in to see them all

38%
Phase 2

Dizal Pharmaceuticals: 3 of its 6 programs at phase 2

  1. EGFR Mutant-specific Inhibitor DZD6008phase 2
  2. GW5282phase 2
  3. Conventional CHOP regimenphase 2
50%

Sino Biopharmaceutical: 31 of its 97 programs at phase 2

  1. JAK2 Inhibitor TQ05105phase 2
  2. TQB2922phase 2
  3. TRD205phase 2
  4. BTK Inhibitor TQB3702phase 2
  5. TQB6411phase 2

and 26 more — sign in to see them all

32%
Phase 3

Dizal Pharmaceuticals: 3 of its 6 programs at phase 3

  1. birelentinibphase 3
  2. sunvozertinibphase 3
  3. golidocitinibphase 3
50%

Sino Biopharmaceutical: 26 of its 97 programs at phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. NTQ5082phase 3
  5. culmerciclibphase 3

and 21 more — sign in to see them all

27%
Approved, new studies00%

Sino Biopharmaceutical: 3 of its 97 programs at approved, new studies

  1. catequentinib hydrochlorideapproved, new study
  2. Adalimumabapproved, new study
  3. TyboWe® Adalimumab Injectionapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Dizal Pharmaceuticals2 readouts · 0 phase 3

Dizal Pharmaceuticals, Nov ’26: 1 program whose next study reaches primary completion

  1. birelentinibphase 3 · Nov 23 · NCT07888569
·········

Dizal Pharmaceuticals, Sep ’27: 1 program whose next study reaches primary completion

  1. EGFR Mutant-specific Inhibitor DZD6008phase 2 · Sep 0 · NCT06905197
·
Sino Biopharmaceutical37 readouts · 10 phase 3

Sino Biopharmaceutical, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868phase 3 · Nov 0 · NCT06767813
  2. NTQ5082phase 3 · Nov 0 · NCT07177859
  3. TQB2252phase 1 · Nov 0 · NCT06649656
  4. TQH2722phase 3 · Nov 0 · NCT07398859

Sino Biopharmaceutical, Dec ’26: 14 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-HER2 Bispecific Antibody TQB2930phase 3 · Dec 0 · NCT06202261
  2. BET Inhibitor TQB3617phase 2 · Dec 0 · NCT06122831
  3. BTK Inhibitor TQB3702phase 2 · Dec 0 · NCT06859931
  4. catequentinib hydrochlorideapproved, new study · Dec 0 · NCT04344158
  5. culmerciclibphase 3 · Dec 0 · NCT05780567

and 9 more — sign in to see them all

Sino Biopharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3 · Jan 0 · NCT06561607
  2. vilzemetkibphase 3 · Jan 0 · NCT06860971

Sino Biopharmaceutical, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB6411phase 2 · Feb 0 · NCT07367516
  2. TQC3721phase 3 · Feb 0 · NCT07464587

Sino Biopharmaceutical, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anecatibin Fumarate Capsulesphase 1 · Mar 0 · NCT07538973
  2. TQB3473phase 3 · Mar 0 · NCT06900920
  3. TQC2938phase 2 · Mar 17 · NCT06789289

Sino Biopharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion

  1. NTQ6179phase 1 · Apr 0 · NCT07909837
  2. TQB3201phase 2 · Apr 0 · NCT07172126

Sino Biopharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. NTB003phase 2 · May 31 · NCT07462130
·

Sino Biopharmaceutical, Jul ’27: 2 programs whose next study reaches primary completion

  1. TQD3524phase 2 · Jul 0 · NCT07512596
  2. TQH3906phase 3 · Jul 0 · NCT06754891

Sino Biopharmaceutical, Aug ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB2916phase 2 · Aug 0 · NCT06962267
  2. TQB6426phase 1 · Aug 0 · NCT07730190
  3. trifluridine tipiracil drug combinationphase 3 · Aug 0 · NCT07483684
  4. LM-168phase 2 · Aug 1 · NCT06868199
  5. KYLO-0603phase 2 · Aug 15 · NCT07878091
·

Sino Biopharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3 · Oct 0 · NCT07179679
  2. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1 · Oct 30 · NCT04740424
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Dizal Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sino Biopharmaceutical

New programs 3

  • NTQ6179phase 1 · first study · Oct 20 · Acromegaly
  • KYLO-0603phase 2 · first study · Sep 24 · Non-alcoholic Fatty Liver Disease
  • TQF6422phase 1 · first study · Aug 26 · Obesity

Reached a new phase 1

  • TQA3605phase 3 · Aug 28 · Hepatitis B, Chronic

Study stopped 0

None

Primary completion later 4

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionDizal PharmaceuticalsSino Biopharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Dizal Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. sunvozertinibphase 3
  2. golidocitinibphase 3
  3. EGFR Mutant-specific Inhibitor DZD6008phase 2

Their studies: Dizal Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Sino Biopharmaceutical in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. vilzemetkibphase 3
  5. FHND-9041phase 3

and 5 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Dizal Pharmaceuticals in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. birelentinibphase 3

Their studies: Dizal Pharmaceuticals’ studies of Lymphoma, Large B-Cell, Diffuse in search

Sino Biopharmaceutical in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. TQB2825phase 3
  2. gemcitabine-oxaliplatin regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Dizal Pharmaceuticals in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. birelentinibphase 3

Their studies: Dizal Pharmaceuticals’ studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Sino Biopharmaceutical in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. Bcl-2 Inhibitor TQB3909phase 3

Their studies: Sino Biopharmaceutical’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Lymphoma, B-Cellboth · compare here

Dizal Pharmaceuticals in Lymphoma, B-Cell: 1 program

  1. sunvozertinibphase 3

Their studies: Dizal Pharmaceuticals’ studies of Lymphoma, B-Cell in search

Sino Biopharmaceutical in Lymphoma, B-Cell: 1 program

  1. TQB3702 tablets+Chemotherapy regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, B-Cell in search

Lymphoma, T-Cell, Peripheralboth · compare here

Dizal Pharmaceuticals in Lymphoma, T-Cell, Peripheral: 1 program

  1. golidocitinibphase 3

Their studies: Dizal Pharmaceuticals’ studies of Lymphoma, T-Cell, Peripheral in search

Sino Biopharmaceutical in Lymphoma, T-Cell, Peripheral: 1 program

  1. gemcitabine-oxaliplatin regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, T-Cell, Peripheral in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Dizal Pharmaceuticals in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. birelentinibphase 3

Their studies: Dizal Pharmaceuticals’ studies of Purpura, Thrombocytopenic, Idiopathic in search

Sino Biopharmaceutical in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. TQB3473phase 3

Their studies: Sino Biopharmaceutical’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Dizal Pharmaceuticals 4 of 6 · Sino Biopharmaceutical 70 of 97 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sino Biopharmaceutical: 19).